Lounge
Connecting…
Connecting…
View all

SELLAS Life Sciences (SLS): REGAL Data and Dilution Risk

What SELLAS Life Sciences (SLS) does, what its Phase 3 REGAL survival data in AML show, the 2027 BLA plan, and the dilution risk from its $150M offering.

StocksTrending6 min read0 viewsPublished Updated
Contents7 sections
  1. What SELLAS Life Sciences develops
  2. How to read the REGAL Phase 3 results
  3. Upcoming SLS stock catalysts
  4. Small-cap biotech risk: cash and dilution
  5. A checklist for the next SELLAS announcement
  6. Frequently asked questions
  7. Sources and references

Key takeaways

  • SELLAS Life Sciences (Nasdaq: SLS) is a clinical-stage oncology company with no approved products; its lead candidate is galinpepimut-S (GPS), a WT1-targeting peptide vaccine.
  • On November 17, 2026, SELLAS said the Phase 3 REGAL trial met its overall survival endpoint: median OS 24.0 vs 14.7 months, hazard ratio 0.59, two-sided p=0.035.
  • This is company-reported topline data, not an approval. No confidence interval or secondary endpoints have been released, and the BLA is targeted for the first half of 2027.
  • After the close the same day, SELLAS launched a $150 million underwritten stock offering plus a $22.5 million underwriter option.
  • Shares outstanding rose about 33% in the first nine months of 2026, to 203.5 million, while cash reached $134.7 million at September 30.

SELLAS Life Sciences (Nasdaq: SLS) is a New York-based, clinical-stage cancer drug developer with no approved products and no product revenue. Its lead candidate is galinpepimut-S (GPS), a peptide vaccine meant to keep acute myeloid leukemia (AML) in remission, and its second program is SLS009 (tambiciclib), a CDK9 inhibitor. On November 17, 2026, the company reported that its Phase 3 REGAL trial hit its overall survival goal, and after the close it launched a $150 million stock offering. Everything below is drawn from company releases and SEC filings, as of November 19, 2026.

The short answer for anyone searching "SLS stock": the readout clears the single biggest hurdle in the company's history, but it is topline data from one small open-label trial, the FDA has not weighed in, and the share count is rising again. Separating what is confirmed from what is planned is the core skill with small-cap biotech.

What SELLAS Life Sciences develops

According to its preliminary prospectus supplement, the corporate entity dates to 2006 and passed through the RXi Pharmaceuticals and Galena Biopharma names before a 2017 combination with SELLAS. Like most pre-revenue biotechs, it has funded research mainly by selling stock.

GPS (galinpepimut-S)

How it works
Four WT1-derived peptides that train CD4+ and CD8+ T cells to attack residual leukemia cells
Status (Nov 2026)
Phase 3 REGAL topline reported Nov 17; primary endpoint met
Next checkpoint
FDA meeting; BLA targeted for 1H 2027; full data at a medical meeting

SLS009 (tambiciclib)

How it works
Highly selective CDK9 inhibitor that blocks survival proteins cancer cells depend on
Status (Nov 2026)
Phase 2 in relapsed/refractory AML completed; 80-patient randomized Phase 2 in newly diagnosed AML enrolling (40 patients as of Nov 5)
Next checkpoint
ASH meeting Dec 12-15, 2026; preliminary topline expected Q4 2026

GPS is licensed from Memorial Sloan Kettering Cancer Center and holds FDA Orphan Drug and Fast Track designations in AML, per company filings. Those designations can speed or ease review, but they say nothing about whether a drug works. SLS009 is licensed from GenFleet Therapeutics for all territories outside Greater China.

How to read the REGAL Phase 3 results

REGAL enrolled 126 AML patients in second or later complete remission who could not get an allogeneic stem cell transplant. They were randomized 1:1 to GPS alone or the investigator's choice of best available treatment (BAT): observation, a hypomethylating agent, venetoclax, low-dose cytarabine, or combinations. The final analysis was pre-set to run after 80 deaths, a threshold SELLAS announced on October 28, 2026.

Median overall survival

Company-reported figure
24.0 months GPS vs 14.7 months BAT
What to keep in mind
A 9.3-month gap in medians describes one point on each survival curve

Hazard ratio

Company-reported figure
0.59 (41% lower risk of death)
What to keep in mind
A rate comparison over time, not 41% fewer deaths

p-value

Company-reported figure
0.035, two-sided
What to keep in mind
Below 0.05 but without much margin; no confidence interval given

Safety

Company-reported figure
Mostly grade 1/2; injection-site reactions most common
What to keep in mind
No adverse event counts or rates published yet

Size

Company-reported figure
126 patients, analyzed at 80 deaths
What to keep in mind
Subgroup results will be noisy

What has not been disclosed

  • The 95% confidence interval and Kaplan-Meier survival curves
  • Secondary endpoints such as leukemia-free survival and measurable residual disease
  • What subsequent therapies control-arm patients received, and full adverse event tables
  • SELLAS says these will come at an upcoming major medical conference and in a peer-reviewed journal, with no date given

In an open-label trial, patients and doctors know the assigned treatment. Overall survival is an objective endpoint, but a control arm that allowed observation alone and differences in later treatment can still shift how regulators read the result. SELLAS lists the risk that the FDA may not agree with its analysis.

Upcoming SLS stock catalysts

Biotech timelines slip often, and REGAL is a good example: enrollment finished in March 2024, the 60-death interim analysis came in December 2024, the data monitoring committee recommended continuing in January 2025, and the 80th death was not announced until October 2026. Treat every date below as a company target.

  1. 1

    Dec 12-15, 2026: ASH Annual Meeting

    SLS009 Phase 2 data in relapsed/refractory AML. The Q3 update previewed a 54% response rate in monocytic AML and 57% in TP53-mutated AML at 30 mg twice weekly. It was a single-arm study, so comparisons to historical benchmarks are loose.

  2. 2

    Q4 2026: SLS009 first-line preliminary data

    Preliminary topline from the 80-patient randomized trial in newly diagnosed AML, which had 40 patients enrolled as of November 5.

  3. 3

    Date not set: FDA meeting and full REGAL data

    SELLAS plans to discuss an accelerated filing strategy with the FDA. Expect an 8-K or press release when that happens.

  4. 4

    1H 2027 target: GPS Biologics License Application

    Contingent on FDA agreement. Acceptance and review would follow, each with its own timeline.

You can track quarterly report dates on the earnings calendar and see how often tickers like SLS come up in stock-focused Telegram channels on the stock Telegram trends page. Chatter volume measures attention, not the quality of trial data.

Small-cap biotech risk: cash and dilution

For a pre-revenue company, cash burn and share issuance decide how much of any success flows to existing holders. SELLAS's Q3 filing makes the pattern clear.

Cash and equivalents

Dec 31, 2025
$71.8M
Sep 30, 2026
$134.7M
Change
Raised through equity

Shares outstanding

Dec 31, 2025
153.1M
Sep 30, 2026
203.5M
Change
About +32.9%

Quarterly net loss (Q3)

Dec 31, 2025
$6.8M (Q3 2025)
Sep 30, 2026
$10.1M
Change
Higher BLA-prep spending

That is roughly 50.4 million new shares in nine months (203,527,833 minus 153,103,459). On top of it comes the $150 million offering and the $22.5 million underwriter option. The 424B5 also shows up to $150 million still available under an at-the-market (ATM) program with TD Securities, about 8.1 million warrants at a $2.07 average exercise price, and about 2.7 million stock options.

  • Price and share count are set at pricing and disclosed in the final 424B5 and an 8-K; the preliminary version left them blank.
  • The company and its officers agreed to a 60-day lock-up; after that, ATM sales can resume.
  • The filing puts the closing price range from Nov 16, 2025 to Nov 16, 2026 at $1.39 to $15.46, with a $7.47 close the day before the readout.
  • SELLAS expects to lose smaller reporting company status on January 1, 2027, which brings fuller disclosure.

Simple math: if quarterly operating expenses stayed at Q3's $11.3 million, September cash would cover about 12 quarters. BLA preparation, manufacturing, and launch costs would shorten that, so treat it as an optimistic reference point.

A checklist for the next SELLAS announcement

  1. Search SELLAS on SEC EDGAR and read the 8-K, usually Item 8.01, plus the attached press release (Exhibit 99.1).
  2. For trial news, note whether the primary endpoint was met, the hazard ratio, p-value, confidence interval, and sample size.
  3. For financing, read the 424B5 for price, share count, discount, lock-up length, and remaining ATM capacity.
  4. Cross-check endpoint definitions on ClinicalTrials.gov using the trial number (REGAL is NCT04229979).
  5. Note the timestamp: the offering hit at 4:01 p.m. ET, after the regular session, so the first full reaction came in after-hours and the next day's trading.

Bottom line: SELLAS Life Sciences now has a positive Phase 3 survival readout, but three open questions remain (the confidence interval, the secondary endpoints, and the FDA's view) alongside a steady pattern of share issuance. Reading each new filing as either a confirmed fact or a company plan is the most practical way to manage risk in a stock like SLS.

Frequently asked questions

Why did SLS stock jump on November 17, 2026?
Before the U.S. market opened, SELLAS filed an 8-K and press release saying its Phase 3 REGAL trial of GPS met its primary endpoint of overall survival in acute myeloid leukemia. At 4:01 p.m. ET the same day it announced a $150 million underwritten public offering, so the good-news readout and the dilution news landed within hours of each other. Pricing of that offering, the full dataset, and the FDA meeting outcome are the next facts that can move the stock.
Does a positive Phase 3 mean FDA approval is likely?
It is a necessary step, not a guarantee. SELLAS itself warns that final analyses may differ from topline results and that the FDA may not agree with its interpretation. REGAL was a single open-label trial of 126 patients with a p-value of 0.035, and the confidence interval has not been published. The FDA still has to agree on the filing path, accept the BLA, and complete a review.
What does a hazard ratio of 0.59 mean?
It means the estimated rate of death over time in the GPS arm was about 59% of the rate in the control arm, which the company describes as a 41% reduction in risk of death. It does not mean 41% fewer patients died. With only 80 deaths analyzed, the plausible range around 0.59 could be wide, which is why the unpublished confidence interval matters.
How much dilution should SLS shareholders expect?
The exact number depends on the offering price, which was blank in the November 17 preliminary prospectus. Beyond the $150 million deal and the $22.5 million option, the filing shows up to $150 million still available under an at-the-market agreement with TD Securities, about 8.1 million warrants at a $2.07 average exercise price, and about 2.7 million options. A 60-day lock-up limits new company sales after the offering.

Sources and references

  1. 1SELLAS: Positive Pivotal Phase 3 REGAL Trial Data (Nov 17, 2026)(opens in a new tab)ir.sellaslifesciences.com
  2. 2SELLAS: Third Quarter 2026 Financial Results (Nov 12, 2026)(opens in a new tab)ir.sellaslifesciences.com
  3. 3SELLAS: Proposed $150.0 Million Underwritten Public Offering (GlobeNewswire)(opens in a new tab)www.globenewswire.com
  4. 4SEC EDGAR: SELLAS Preliminary Prospectus Supplement (424B5, Nov 17, 2026)(opens in a new tab)www.sec.gov